As loss of p53 function contributes to resistance of some tumour cells to TNF-induced cytotoxicity (Cai et al, 1997), the present study suggests that combination of TNF with mithramycin may be a potential strategy to sensitise mutant p53 TNF-resistant tumour cells. The gene discussed is TP53; the disease is neoplasm.